One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Liquidia Corporation logo
Liquidia Corporation LQDA
$ 51.37 7.69%
report update icon

Quarterly report 2026-Q3
added 11-10-2026

Liquidia Corporation Income Statement 2025-2011 | LQDA

Brief overview of financial performance at Liquidia Corporation

The conclusions below are based on five years of reported results. According to figures from Liquidia Corporation, revenue changed from 0.7 dollars to 158 million dollars over five years. Across the full period, sales moved by +21394594494.6%; the average annual rate was 4535.1%. Sales grew at a rate typical of a strong expansion phase.

EBITDA changed from $3.1 thousand to −$49.8 million (−1623554.2%). EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 414931.1% to −31.5%. Cost pressure reduced operating profitability.

The final result was −$59.8 initially and −$68.9 million in the final year. The negative result deepened, showing weaker final efficiency.

Market capitalization changed from $103 million to $2.9 billion (+2749.2%). Capitalization grew more slowly than the underlying results.

Overall conclusion

The current trajectory does not yet confirm a sustainable recovery. The strongest signals are revenue expansion. The weaker side of the profile includes limited operating profitability, lower net income and weaker operating efficiency. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Liquidia Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.95 B 2.7 B 957 M 440 M 242 M 103 M 105 M 98.9 M - - - - - - -

Shares

86.1 M 78.7 M 65 M 61 M 49.7 M 37.8 M 18.5 M 7.16 M - - - - - - -

Historical Prices

34.2 34.2 14.7 7.22 4.87 2.95 4.28 21.7 - - - - - - -

Net Income

-68.9 M -130 M -78.5 M -41 M -34.6 M -59.8 -47.6 M -53.1 M -29.2 M -15.9 M - - - - -

Revenue

158 M 14 M 17.5 M 15.9 M 12.9 M 0.74 8.07 M 2.71 M 7.26 M 13.2 M - - - - -

Cost of Revenue

- 5.88 M 2.89 M 2.86 M 3.02 M 238 K - - - - - - - - -

Gross Profit

- 8.12 M 14.6 M 13.1 M 9.83 M 0.502 7.26 M 2.59 M 6.94 M 12.3 M - - - - -

Operating Income

-51.4 M -121 M -73.4 M -38.8 M -33.8 M -59.1 M -46.8 M - - - - - - - -

Interest Expense

- - 6.27 M 2.34 M 762 K 858 K 1.37 M - - - - - - - -

EBITDA

-49.8 M -119 M -71.2 M -35.1 M -28.2 M 3.07 K -44.3 M -33.3 M -27.1 M -15.2 M - - - - -

Operating Expenses

51.4 M 129 M 88 M 51.8 M 43.6 M 59.6 54.1 M 37.5 M 35 M 28.2 M - - - - -

General and Administrative Expenses

157 M 81.6 M 44.7 M 32.4 M 23.1 M 27.4 M 13.6 M 8.75 M 10.2 M 4.84 M - - - - -

All numbers in USD currency

Quarterly Income Statement Liquidia Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

89.5 M 88.9 M 88 M 358 K 86.3 M 85.6 M 85.2 M 1.99 M 78.3 M 76.4 M 75.4 M 226 K 64.9 M 64.8 M 64.7 M 1.21 M 64.5 M 62.2 M 52.5 M -96.7 M 52.1 M 50.8 M 43.4 M 43.3 M 37.8 M 28.5 M 28.4 M 28.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-236 M 74.7 M 52.9 M 14.6 M -3.53 M -41.6 M -38.4 M -38.5 M -31 M -28.7 M -30.1 M -27.4 M -15.8 M -23.5 M -11.7 M -6.53 M -9.09 M -9.45 M -15.9 M -11.6 M -7.28 M -6.55 M -9.18 M - -15 M -13.9 M -14.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

225 M 172 M 133 M 92 M 54.3 M 8.84 M 3.12 M 2.92 M 4.45 M 3.66 M 2.97 M 4.53 M 3.68 M 4.79 M 4.49 M 5.36 M 3.16 M 3.92 M 3.49 M 3.22 M 3.18 M 3.38 M 3.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - 1.52 M 1.35 M 1.56 M 1.49 M 1.47 M 993 K 570 K 671 K 654 K 694 K 740 K 731 K 694 K 726 K 890 K 714 K 694 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - 1.6 M 1.56 M 2.88 M 2.17 M 1.5 M 3.54 M 3.11 M 4.12 M 3.84 M 4.67 M 2.42 M 3.19 M 2.8 M 2.49 M 2.29 M 2.66 M 2.39 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-264 M 85.5 M 61.5 M 19.8 M 1.77 M -37.5 M -35.4 M -36.1 M -29.2 M -27.2 M -28.8 M -26.4 M -14.9 M -22.8 M -9.23 M -6.5 M -8.83 M -8.97 M -14.5 M -11.4 M -7.08 M -6.35 M -9 M - -14.8 M -13.7 M -14.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - 3 M 2.6 M 2.52 M 1.96 M 1.76 M 1.43 M 1.12 M 698 K 620 K 542 K 478 K 204 K 205 K 203 K 150 K - 191 K 211 K 255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-263 M 85.8 M 61.6 M 19.8 M 1.87 M -37.4 M -35.2 M -36 M -29.1 M -27.1 M -28.7 M -26.3 M -14.8 M -22.7 M -9.13 M -6.4 M -8.63 M -8.77 M -14.3 M -11.6 M -6.68 M -5.95 M -8.5 M - -12.6 M -12.3 M -13.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - -61.5 M - -1.77 M 37.5 M 37 M 37.7 M 32.1 M 29.4 M 30.3 M 30 M 18 M 26.9 M 13.1 M 11.2 M 11.3 M 12.2 M 17.3 M 13.9 M 9.37 M 9.02 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

59 M 57.4 M 46.9 M 48.2 M 40.1 M 38.8 M 30.1 M 21.2 M 20.2 M 19.9 M 20.2 M 17.1 M 10.6 M 9.24 M 7.79 M 6.19 M 6.74 M 6.94 M 12.5 M 8.47 M 4.88 M 4.42 M 5.34 M - 7.15 M 5.23 M 3.82 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Liquidia Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.2 -0.71 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 293.87 0.19 % $ 520 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 151.6 -3.2 % $ 19.9 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 302.6 -0.19 % $ 23.6 B usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 45.05 -9.97 % $ 4.05 B schweizSchweiz
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.48 -5.96 % $ 5.56 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.96 -3.71 % $ 640 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.8 1.06 % $ 128 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 7.4 -0.13 % $ 113 M australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 30.68 -1.81 % $ 2.04 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.0 -6.76 % $ 48.8 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 317.26 0.99 % $ 6.14 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 432.7 1.47 % $ 1.29 T usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.0 -3.06 % $ 16.9 B australiaAustralia
CorMedix CorMedix
CRMD
$ 5.37 -2.1 % $ 387 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
MannKind Corporation MannKind Corporation
MNKD
$ 4.22 0.84 % $ 1.29 B usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
MediciNova MediciNova
MNOV
$ 1.4 -4.76 % $ 68.7 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 147.75 -0.68 % $ 370 B usaUSA
Moderna Moderna
MRNA
$ 250.79 -6.77 % $ 97.6 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 11.18 -7.72 % $ 1.21 B usaUSA
Novartis AG Novartis AG
NVS
$ 163.39 -0.18 % $ 317 B schweizSchweiz
Omeros Corporation Omeros Corporation
OMER
$ 17.3 -1.48 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.97 -0.75 % $ 164 M israelIsrael
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.13 -3.22 % $ 407 M usaUSA